研究者基本情報

氏名

• 氏名

  Yukinari HAYASHI

ホームページ・researchmap等のリンク

• ホームページ・researchmap等のリンク

  ホームページのリンク

所属・職名

• Department of Economics, Professor

学歴

• Apr. 1998, Mar. 2004, Hitotsubashi University, Graduate School of Economics
• 1996, Rikkyo University, College of Economics, Department of Economics

学位

• 28 Mar. 2000, 修士（経済学）, 一橋大学, 経済学関係

職歴

• Apr. 2024, Kokugakuin University, Faculty of Economics
• Apr. 2020, Mar. 2024, Hiroshima International University
• Oct. 2019, Mar. 2024, Hiroshima University, Faculty of Economics
• Apr. 2018, Mar. 2024, Okayama University, Graduate School of Interdisciplinary Science and Engineering in Health Systems
• Apr. 2016, Mar. 2020, Hiroshima International University
• Apr. 2011, Mar. 2016
• Apr. 2009, Mar. 2011
• Apr. 2004, Mar. 2009, Hiroshima International University, Faculty of Health and Welfare, Department of Health Services Management
• Apr. 2003, Mar. 2004, Toyo University, Faculty of Economics, Department of Economics
• Apr. 2003, Mar. 2004

本学就任年月日

• 01 Apr. 2024

研究活動

論文

• 3, 25, 38, Mar. 2024
• 18, 141, 187, Oct. 2023
• 18, 189, 223, Oct. 2023
• 14, 29, 40, Apr. 2021

  関連URL
• Wholesale price and marketing channel type of prescription drugs, Sakurai Hidehiko; Tanno Tadanobu; Masuhara Hiroaki; Hayashi Yukinari; Yamada Akira, JSMD Review, 3, 1, 11, 18, 2019, Japan Society of Marketing and Distribution

  DOI
• Distribution Analysis for Prescription Medicines:Empirical study on wholesaler functions and information provision, Sakurai Hidehiko; Tanno Tadanobu; Masuhara Hiroaki; Hayashi Yukinari; Onda Mitsuko; Yamada Akira, Journal of Marketing & Distribution, 19, 1, 15, 24, 2016, Japan Society of Marketing and Distribution

  DOI
• 9, 1, 47, 56, 2016
• 5, 1, 1, 8, 2015
• 8, 115, 127, 2015
• The Performance-related Compensation System in Health Care System, 7, 1, 15, 22, 2013
• Statistical Cost Allocation in Health Care Management Using Finite Mixture Models, 7, 1, 23, 29, 2013
• 15, 151, 175, 2013
• Pharmaceutical Distribution, Price Regulation, and Bargaining Power, 5, 17, 30, 2012
• Moral motivation in public economic activities, The Economic review, 61, 4, 1, 19, 2011
• Welfare analysis of functional division among medical facilities, Japanese journal of health economics & policy, 22, 1, 79, 90, 2010
• 3, 25, 40, 2010
• Decentralization and reform of public owned hospitals, The bulletin of Department of Health Services Management, Hiroshima International University, 2, 11, 26, 2009
• 1, 9, 20, 2008
• Brief consideration on the effect of consolidation of public owned hospitals, The bulletin of Department of Health Services Management, Hiroshima International University, 1, 1, 8, 2008
• 第8号, 8, 13, 16, 2005
• 2005
• 14, 3, 127, 138, 2004

  DOI
• Economic Analysis on Mixed Treatment Prohibition, HAYASHI Yukinari; YAMADA Akira, Journal of Health Care and Society, 13, 3, 73, 85, 2003, The Health Care Science Institute, The Japanese Health Care system basically does not allow the insured to enjoy uninsured medical service. If they do receive it for some sickness or injury, they usually cannot receive any insurance money for the matter even when they are also given insured medical service for it. Thus the system prohibits not only uninsured medical service but also a mixture of insured and uninsured medical services. The aim of the paper is to assess the institutional effects of the mixed treatment prohibition of the Japanese Health Care system from an economic point of view. We formulate a simple theoretical model and study the differences of mixed treatment prohibition and permitted mixed treatment. For the latter, we have the case in mind that if the insured are given both insured and uninsured medical service, they receive insurance money only for insured medical service. Through the comparative institutional analysis, we obtained two main results: (1) the higher the average income level of the insured or the cheaper the medical service, the more socially desirable the permission of mixed treatment, and (2) there is the case that the mixed treatment permission rather reinforces medical equality: the difference between the levels of medical service chosen by the insured with the lowest income and by those of the highest income, decreases when the insured of the lowest income choose the highest level of insured medical service under the mixed treatment prohibition. It has been taken for granted that the mixed treatment prohibition together with the public compulsory insurance system contribute to medical equality in Japan. The second result suggests that we should accept the idea with some reservations.

  DOI
• Medical Expense Variations and Standardization of Medical Treatments:Comparative Analysis Using the Receipt Data on Renal Failure, Hosoya Kei; Hayashi Yukinari; Kon-no Hiroki; Tokita Tadahiko, Iryo To Shakai, 12, 2, 121, 137, 2002, The Health Care Science Institute, In this paper, we use the claim data, which is based on the receipt of the National Health Insurance member, and clarify medical expense variations among both areas and medical institutions in three prefectures: Hokkaido, Chiba, and Fukuoka. The important problem, which is often pointed out in receipt-based medical studies, is the fact that there could be inconsistency between the disease name recorded in the receipt and the name of the disease actually affecting patients. Owing to this problem, we analyzed medical expense variations using renal failure data that is expected to resolve the inconsistency problem. Our main conclusions are listed below. (1) In full-sample analysis, we confirmed. medical expense variations among three prefectures for both inpatient and outpatient treatment. In particular, we captured obvious variations between the high medical expense area of Hokkaido and the lower one of Chiba. Moreover, as for outpatient treatmet in Fukuoka, we observed a possibility that treatments with low medical expense are excessively supplied compared with other prefectures. (2) When we concentrate our study on the institutions with high receipt, the clinical uniformity among medical institutions was observed simultaneously with low expense characteristics in Chiba. Therefore, some causality will be derived from this relationship. (3) From study on chronic renal failure in dialysis patients, it was clear that the standardization of the way of medical treatment would lead to the equality of medical expenses. This gives one active basis about the validity of DRGs/PPS.

  DOI
• 53, 3, 226, 235, 2002

Misc

• 7, 45, 58, 2014
• 6, 53, 60, 31 Mar. 2013
• 4, 129, 138[含 抄録], 2011
• The efficiency of the mixed medical service delivery system, The bulletin of Department of Health Services Management, Hiroshima International University, 4, 37, 48, 2011

著書等出版物

• Feb. 2019
• 01 Nov. 2018
• Dec. 2014
• 01 Feb. 2009
• 01 Mar. 2008
• 01 Feb. 2008
• 26 Aug. 2005
• 01 Aug. 2004

競争的資金

• 23K01718
• 22K01466, Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Investigating the relationship between competition and protection for the creation and dissemination of innovation
• 21K01554, Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Economic analysis of public hospital reform and community medicine
• 16K03647, Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Vertical Transaction Theory Influenced by Innovation and regulation: Toward Good Pharmaceutical Industry, The following are empirically clarified about the form of wholesale transactions between hospitals and pharmacies about prescription drugs and their delivery price. The large scale of a medical institution tends to change the transaction from the single item price to the total price of all items (uniform discount). When the wholesaler that is "main" wholesaler of the medical institution receives capital from the pharmaceutical manufacturer, the wholesaler sets low discount rate of the delivery price of the drug that the manufacturer makes. In the theoretical analysis, we discover that when both R&D investment and spillover effects are high, the economic welfare of monopoly is higher than that of Cournot competition or Stackelberg competition. In the patent analysis, we find that when the degree of patent protection is low, in doctrines of damages of patent infringement an innovator favors lost profit system over unjust enrichment.
• 26380387, Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Design of Health Policy Based on Moral Motivation, This study clarify the role of moral motivation in providing health services and analyzes the health policy. Firstly, we confirm an incentive to shorten inpatient day excessively under DPC/PDPS when medical institutions behave as profit maximizer, and show that moral motivation is an important factor for diffusion of DPC/PDPS. The study also indicates that to stimulate moral motivation is critical factor for increasing the number of medical institutions with moral motivation.

  関連URL
• 25380317, Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Economic analysis of medical pharmaceutical distribution, To obtain a qualitative results about how to affect the profit of the upstream pharmaceutical manufacturer by the difference in bargaining power between the pharmaceutical wholesaler and medical institution in the theory part. Under the current drug pricing system bargaining power is higher upstream pharmaceutical manufacturer profit of wholesale increases. The main conclusion by empirical analysis, the probability of the total value traded the larger the scale of hospitals and pharmacies is that the increases. On the other hand, the probability that the number of wholesale to trade shifts to the single item unit price traded higher utilization rate of more or generic drugs is higher. Four ethical pharmaceutical wholesale offers a variety of information to the upstream pharmaceutical manufacturers, it was revealed that its consideration has become a source of big profits.

  関連URL
• 23K01718
• 22K01466, Investigating the relationship between competition and protection for the creation and dissemination of innovation
• 21K01554, Economic analysis of public hospital reform and community medicine
• 16K03647, Vertical Transaction Theory Influenced by Innovation and regulation: Toward Good Pharmaceutical Industry, The following are empirically clarified about the form of wholesale transactions between hospitals and pharmacies about prescription drugs and their delivery price. The large scale of a medical institution tends to change the transaction from the single item price to the total price of all items (uniform discount). When the wholesaler that is "main" wholesaler of the medical institution receives capital from the pharmaceutical manufacturer, the wholesaler sets low discount rate of the delivery price of the drug that the manufacturer makes.;In the theoretical analysis, we discover that when both R&D investment and spillover effects are high, the economic welfare of monopoly is higher than that of Cournot competition or Stackelberg competition. In the patent analysis, we find that when the degree of patent protection is low, in doctrines of damages of patent infringement an innovator favors lost profit system over unjust enrichment.
• 26380387, Design of Health Policy Based on Moral Motivation, This study clarify the role of moral motivation in providing health services and analyzes the health policy. Firstly, we confirm an incentive to shorten inpatient day excessively under DPC/PDPS when medical institutions behave as profit maximizer, and show that moral motivation is an important factor for diffusion of DPC/PDPS. The study also indicates that to stimulate moral motivation is critical factor for increasing the number of medical institutions with moral motivation.
• 25380317, Economic analysis of medical pharmaceutical distribution, To obtain a qualitative results about how to affect the profit of the upstream pharmaceutical manufacturer by the difference in bargaining power between the pharmaceutical wholesaler and medical institution in the theory part. Under the current drug pricing system bargaining power is higher upstream pharmaceutical manufacturer profit of wholesale increases. The main conclusion by empirical analysis, the probability of the total value traded the larger the scale of hospitals and pharmacies is that the increases. On the other hand, the probability that the number of wholesale to trade shifts to the single item unit price traded higher utilization rate of more or generic drugs is higher.;Four ethical pharmaceutical wholesale offers a variety of information to the upstream pharmaceutical manufacturers, it was revealed that its consideration has become a source of big profits.
• JP23K01718
• JP22K01466, Investigating the relationship between competition and protection for the creation and dissemination of innovation
• JP21K01554, Economic analysis of public hospital reform and community medicine, This study examined the significance and impact of public hospitals from the perspective of the community medicine. First, we showed theoretically that if public hospital reform results in an increased pursuit of self-interest, it may have a negative impact on the community medicine. In addition, the current Japanese drug price system has institutional complementarity with the public hospital reform in terms of drug price reductions, and we clarified the impact of the public hospital reform to drug price reduction. Furthermore, we found that the proportion of public hospitals were significantly related to the number of deaths per population due to COVID-19 in each prefecture, empirically suggesting the importance of public hospitals in a pandemic.

学外活動

学協会活動

• JAPAN SOCIETY FOR HEALTHCARE ADMINISTRATION
• JAPANESE ECONOMIC ASSOCIATION
• JAPAN HEALTH ECONOMICS ASSOCIATION
• JAPAN SOCIETY FOR HEALTH CARE MANAGEMENT

学外委員等活動

• Apr. 2023, 9999, 広島赤十字・原爆病院, 地域医療支援病院運営委員会委員
• Mar. 2023, 9999, 広島県看護協会, 将来構想検討委員会委員
• Jun. 2022, Dec. 2022, 広島県, 高度医療・人材育成拠点の運営形態のあり方検討会 委員
• Nov. 2021, Oct. 2022, 日本学術振興会, 科学研究費委員会専門委員
• Apr. 2014, Mar. 2021, 全国健康保険協会広島県支部, 健康づくり推進委員会委員長
• Oct. 2016, Mar. 2017, 広島市立病院機構, 広島市立新安佐市民病院（仮称）基本設計業務公募型プロポーザル審査委員会副委員長
• Apr. 2016, Mar. 2017, 広島県, ヘルスケアポイント制度検討委員会委員長
• Apr. 2007, Mar. 2008, 岡山市, 岡山市民病院あり方専門会議専門委員